ArticleCell reports. Medicine2021
Serological analysis reveals an imbalanced IgG subclass composition associated with COVID-19 disease severity.
Article in Cell reports. Medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 75 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
75 citing papers in PubMed.
- Human primary antibody response to vaccination follows a partially sequential class-switching program with a checkpoint at IGHG2.Cell reports. Medicine · 2026Article
- Antibody Transcytosis and Neutralizing Activity in Respiratory Epithelial Cells.bioRxiv : the preprint server for biology · 2026Article
- Measuring Humoral Immune Responses to SARS-CoV-2: A Comprehensive Review of Serological Assays.Vaccines · 2026Review
- Coordinated immune response distinguishes duration of SARS-CoV-2 viral particle shedding in humans.iScience · 2026Article
- SARS-CoV-2 Anti-Spike IgG Subclass Titres in a Population with Prior Exposure to Perfluorooctanoic Acid (PFOA).Toxics · 2026Article
- C3d Complement Activation and Antibody Immunity in Convalescent COVID-19: Insights From Adults and Children.Journal of immunology research · 2026Article
- Reduced Fc-mediated antibody responses after COVID-19 mRNA vaccination in a cohort of people living with HIV-1.Scientific reports · 2025Observational
- In vitro complement activation via nucleocapsid and spike proteins of SARS-CoV-2 in COVID-19 patients.Scientific reports · 2025Article
- Temporal correlations between RBD-ACE2 blocking and binding antibodies to SARS-CoV-2 variants in CoronaVac-vaccinated individuals and their persistence in COVID-19 patients.Scientific reports · 2025Article
- Comprehensive analysis of human coronavirus antibody responses in ICU and non-ICU COVID-19 patients reveals IgG3 against SARS-CoV-2 spike protein as a key biomarker of disease severity.Journal of medical microbiology · 2025Article
- Best in Class: IgG as a Treatable Trait for Exacerbation Prevention in Chronic Obstructive Pulmonary Disease.American journal of respiratory and critical care medicine · 2025Article
- Spike specific IgG3 and nucleocapsid IgG response in serum serve as distinguishing immunological markers between SARS-CoV-2 infection and vaccination.Frontiers in immunology · 2025Article
- Humoral immune response to COVID-19 vaccines in onchocerciasis-infected individuals: a field study from Ghana.Frontiers in immunology · 2025Article
- Temporal dynamics of SARS-CoV-2 antibodies and IgG subclasses following multiple doses and diverse COVID-19 vaccine combinations.Frontiers in immunology · 2025Article
- Understanding antibody magnitude and durability following vaccination against SARS-CoV-2.Mathematical biosciences · 2024Article
- Primary SARS-CoV-2 variant of concern infections elicit broad antibody Fc-mediated effector functions and memory B cell responses.PLoS pathogens · 2024Article
- Clinical and Diagnostic Features of Post-Acute COVID-19 Vaccination Syndrome (PACVS).Vaccines · 2024Article
- Inflammatory and Autoimmune Aspects of Multisystem Inflammatory Syndrome in Children (MIS-C): A Prospective Cohort Study.Viruses · 2024Article
- Quantitating SARS-CoV-2 Neutralizing Antibodies from Human Dried Blood Spots.bioRxiv : the preprint server for biology · 2024Article
- Non-neutralizing functions in anti-SARS-CoV-2 IgG antibodies.Biomedical journal · 2024Review
15 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
Abstract
Coronavirus disease 2019 (COVID-19) is associated with a wide spectrum of disease presentation, ranging from asymptomatic infection to acute respiratory distress syndrome (ARDS). Paradoxically, a direct relationship has been suggested between COVID-19 disease severity and the levels of circulating severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific antibodies, including virus-neutralizing titers. A serological analysis of 536 convalescent healthcare workers reveals that SARS-CoV-2-specific and virus-neutralizing antibody levels are elevated in individuals that experience severe disease. The severity-associated increase in SARS-CoV-2-specific antibody is dominated by immunoglobulin G (IgG), with an IgG subclass ratio skewed toward elevated receptor binding domain (RBD)- and S1-specific IgG3. In addition, individuals that experience severe disease show elevated SARS-CoV-2-specific antibody binding to the inflammatory receptor FcɣRIIIa. Based on these correlational studies, we propose that spike-specific IgG subclass utilization may contribute to COVID-19 disease severity through potent Fc-mediated effector functions. These results may have significant implications for SARS-CoV-2 vaccine design and convalescent plasma therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.